Skip to main content

Table 3 Results of cost analyses of glatiramer acetate and interferon-β

From: Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

Costs/patient

Interferon-β

Glatiramer acetate

Cost difference (interferon-β versus glatiramer acetate)

Disease modifying treatment

6.225.96€

4,335.94€

1,890.02€

Spasticity treatment

147.63€

61.42€

86.21€

Relapse management

704.43€

273.95€

430.48€

Total cost/patient

7,078.02€

4,671.31€

2,406.71€

  1. The cost analyses are expressed in 2014 euros (€)